Five Under 5: Top Oncology Videos for the Week of 7/13

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

Zidesamtinib in TKI-Pretreated, Advanced, ROS1+ NSCLC: Joshua K. Sabari, MD

Joshua K. Sabari, MD, an assistant professor in the Department of Medicine at the NYU Grossman School of Medicine; and the director of High Reliability Organization Initiatives at the NYU Perlmutter Cancer Center, detailed efficacy findings from the phase 1/2 ARROS-1 trial (NCT05118789) evaluating the selective ROS1 inhibitor zidesamtinib (NVL-520) in patients with advanced ROS1-positive non–small cell lung cancer (NSCLC).

Data showed patients in the TKI-pretreated population (n = 71) achieved an overall response rate (ORR) of 44%, including 2 complete responses. Patients who received at least 2 prior ROS1 TKIs (n = 51) had an ORR of 41%.

Results from a Q-TWiST Analysis of Belzutifan vs Everolimus in Previously Treated Advanced RCC: Thomas Powles, MD

Thomas Powles, MD, a professor of genitourinary oncology and director of Barts Cancer Centre in London, discussed results from a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of belzutifan (Welireg) vs everolimus (Afinitor) in patients with previously treated advanced renal cell carcinoma (RCC). Findings from the phase 3 LITESPARK-005 trial (NCT04195750) showed a statistically significant and clinically meaningful improvement in patients treated with belzutifan compared with everolimus.

Unmet Needs for Brain Metastases in HER2+ Metastatic Breast Cancer: Erika P. Hamilton, MD

Erika P. Hamilton, MD, the director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, discussed unmet needs regarding treatment for brain metastases in patients with HER2-positive breast cancer and how recent advancements have helped address some of these challenges. She highlighted the central nervous activity that has been displayed by fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu), along with the phase 3 HER2CLIMB trial (NCT02614794) regimen of tucatinib (Tuksya) in combination with trastuzumab (Herceptin) and capecitabine.

Givastomig Plus Nivolumab/mFOLFOX in Metastatic Gastric, Esophageal, and GEJ Adenocarcinoma: Samuel J. Klempner, MD

Samuel J. Klempner, MD, a gastrointestinal medical oncologist at Massachusetts General Hospital Cancer Center and associate professor of medicine at Harvard Medical School, discussed preliminary safety and efficacy findings from a phase 1b trial (NCT04900818) evaluating the bispecific antibody givastomig in combination with nivolumab (Opdivo) and modified FOLFOX (mFOLFOX) in patients with metastatic gastric, esophageal, or gastroesophageal junction adenocarcinoma.

Findings showed the overall response rate was 71% in patients treated with givastomig at doses of 5 mg/kg, 8 mg/kg, or 12 mg/kg (n = 17), with responses achieved irrespective of PD-L1 combined positive score or CLDN18.2 expression. Data also demonstrated that at a median follow-up of 9.0 months, patients experienced a 6-month progression-free survival (PFS) rate of 72.9% (95% CI, 42.6%-89.0%); the median PFS and duration of response were both not evaluable.

Elranatamab Plus Daratumumab/Lenalidomide in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma: Amrita Krishnan, MD

Amrita Krishnan, MD, the Nason-Hollingsworth Endowed Chair for Multiple Myeloma, director of the Judy and Bernard Briskin Multiple Myeloma Center, and a professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, as well as executive medical director of Hematology at City of Hope Orange County, detailed safety and efficacy findings from part 1 of the phase 3 MagnetisMM-6 trial (NCT05623020), which is evaluating elranatamab-bcmm (Elrexfio) in combination with daratumumab (Darzalex) and lenalidomide (Revlimid) in patients with newly diagnosed multiple myeloma who are ineligible for transplant.

Findings showed patients treated with the triplet (n = 36) experienced a confirmed ORR of 97.3% (95% CI, 85.8%-99.9%), including a complete response (CR) or stringent CR (sCR) rate of 27.0%. Notably, responses deepened over time, with the sCR rate improving from 2.7% at an earlier 4.6-month follow-up analysis to 8.1% in the most recent analysis with a median follow-up of 7.9 months.